Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained With 8-Week Dose Interruption
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Investigative Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained With 8-Week Dose Interruptions: A Model-Based Evaluation
J Invest Dermatol 2020 Sep 22;[EPub Ahead of Print], P Chanu, L Musib, X Wang, S Cheeti, S Girish, R Bruno, T Lu, J Reddy, JY Jin, I CaroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.